(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
phase II trial is studying how well GDC-0449 works in treating younger patients
with recurrent or refractory medulloblastoma. GDC-0449 may slow the growth of
the ages of 3 and 21 with a histologically confirmed diagnosis of medulloblastoma that
is recurrent, progressive, or refractory to standard therapy and for which
there is no known curative therapy.
For more information
Hospital Medical CenterDivision
Burnet Ave., Cincinnati, OH 45229-3039Phone:
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center